IGF2BP3 May Contributes to Lung Tumorigenesis by Regulating the Alternative Splicing of PKM

Abstract

RNA binding proteins (RBPs) play a key role in genome regulation. Here we report the post-transcript regulation of IGF2BP3, which belongs to the insulin-like growth factor 2 mRNA binding protein family. We used iRIP-seq and RNA-seq to analyze the transcript regulation and alternative splicing on IGF2BP3 treated with overexpression cells and control. Overexpressed IGF2BP3 has broadly increased genes expression which involved in G-protein coupled receptor signaling pathway, positive regulation of cell proliferation, and signal transduction. IGF2BP3 regulated alternative splicing of multiple genes mainly clustered at response to hypoxia, negative regulation of transcription, and embryonic development. This study first provides alternative splicing analysis on transcription level of IGF2BP3 regulation, which laid the foundation for later research on IGF2BP3 critical functions.

A New RBPs-Related Signature Predicts the Prognosis of Colon Adenocarcinoma Patients

“…RBPs are a group of genes that regulate the growth, development and survival of cancer cells, and are closely related to cancer progression ( 30 , 31 ). For instance, IGF2BP3 may contributes to lung tumorigenesis by regulating the alternative splicing of PKM ( 32 ), HuR promotes the progression of head and neck squamous cell carcinoma and bladder cancer ( 33 , 34 ). Therefore, RBPs are potential biomarkers that most likely predict cancer risk and survival outcomes.…”

Structures and target RNA preferences of the RNA-binding protein family of IGF2BPs: An overview

“…Members of the family of insulin-like growth factor 2 mRNA-binding proteins (IMPs, IGF2BPs) are RNA-binding proteins (RBPs) and often summarized in the VICKZ (Vg1 RBP/Vera, IMP-1,2,3, CRD-BP, KOC, ZBP1) group of RBPs (Yisraeli, 2005). A plethora of studies on IMPs describes their functional contexts, including mRNA transport (Eom et al, 2003;Farina et al, 2003;Kwon et al, 2002;Nielsen et al, 2001;Song et al, 2015), mRNA protection (Doyle et al, 1998;Jonson et al, 2014;Muller et al, 2018;Weidensdorfer et al, 2009), progression of various cancers (Doyle et al, 1998;Ioannidis et al, 2003Ioannidis et al, , 2005Liao et al, 2004;Wu et al, 2019), alternative splicing (Xueqing et al, 2020), diabetes and fatty acid metabolism (Regue et al, 2019), and m 6 A-methylation (Huang et al, 2018b). Other overview articles summarize these functions in an integrative (Bell et al, 2013;Degrauwe et al, 2016;Tong et al, 2018) or paralog-focused manner (Christiansen et al, 2009;Dai, 2020;Findeis-Hosey and Xu, 2012;Huang et al, 2018b;Lederer et al, 2014;Mancarella and Scotlandi, 2019;Wang et al, 2021;Xie et al, 2021).…”

Identification of Primary and Metastatic Lung Cancer-Related lncRNAs and Potential Targeted Drugs Based on ceRNA Network

“…In primary or metastatic cancer, mRNAs IGF2BP3 , HOXA9 , HOXA10 , CEBPG competed with HOXA11-AS mutually, and HOXA10 ( Figure 6B ) as well as IGF2BP3 ( Figure 6C ) were also continuously up-regulated among normal-primary-metastatic process with significant difference in variance analysis. Currently, some studies have demonstrated the association among HOXA10 , IGF2BP3 , and lung cancer ( 29 , 30 ). The results further validated the importance of competitive relationships among HOXA11-AS , IGF2BP3 , and HOXA10 in lung cancer progression.…”